|
India’s pharmaceutical industry is at a pivotal juncture, blending a rich legacy of affordable healthcare with unprecedented opportunities for global leadership. As the world’s third-largest pharmaceutical producer by volume and fourteenth by value, India supplies 20 per cent of global generic medicines, making it a crucial pillar of international healthcare delivery. This in-depth analysis explores the current landscape, growth drivers, challenges, and future prospects of the Indian pharmaceutical sector, highlighting key opportunities in formulations, APIs, R&D, digital health, and global partnerships.
India’s pharmaceutical landscape: Scale, reach and Impact
Global standing and economic contribution
India’s pharmaceutical sector has demonstrated remarkable resilience and growth, registering a 7.8 per cent year-on-year revenue increase in April 2025, with total sales reaching ?19,711 crore. The industry’s turnover in 2023-24 stood at Rs 4.17 lakh crore, sustaining a double-digit growth trajectory over the past five years. This robust expansion has translated into:
- Wider access to affordable medicines
- Enhanced healthcare delivery
- Job creation across the pharmaceutical value chain
India’s role as the “Pharmacy of the World” is underscored by its supply of over 20 per cent of the world’s generic medicines and 55–60 per cent of UNICEF’s vaccine requirements. More than 3,000
drug companies and 10,500 manufacturing units operate in the country, including the highest number of USFDA-approved plants outside the United States.
Domestic market dynamics
The domestic pharmaceutical market is projected to grow at a CAGR of 10–12 per cent until 2030, driven by rising healthcare awareness, increasing prevalence of chronic diseases, and expanding insurance coverage. The sector’s growth is also propelled by the demand for affordable drugs among India’s predominantly middle-class population, which prefers generics over branded medicines due to cost considerations.
Growth drivers: What fuels India’s pharma engine?
Cost efficiency and manufacturing prowess
India’s pharmaceutical industry thrives on a unique combination of low manufacturing costs (30–35 per cent less than in the US and Europe), affordable skilled labor, and cost-effective R&D (up to 87 per cent cheaper than developed countries). These factors have enabled Indian companies to offer high-quality medicines at competitive prices globally.
Policy support and government initiatives
Government schemes have been instrumental in bolstering the sector’s growth. The Production Linked Incentive (PLI) Scheme for pharmaceuticals, with an outlay of Rs15,000 crore, supports 55 projects focused on high-end drugs, including treatments for cancer and diabetes. Another PLI scheme, worth Rs 6,940 crore, targets raw materials like Penicillin G, aiming to reduce import dependency for critical APIs.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) operates over 15,000 Jan Aushadhi Kendras, providing generic medicines at prices up to 80 per cent lower than branded alternatives, significantly improving affordability for the public.
Innovation and R&D momentum
Indian pharmaceutical companies are increasingly investing in R&D, particularly in biotech, biosimilars, and complex generics. The sector has witnessed a surge in AI-driven drug discovery, clinical trials, and precision medicine, positioning India as a hub for pharmaceutical innovation.
Digital health transformation The rapid adoption of digital technologies is reshaping healthcare delivery. Initiatives like the Ayushman Bharat Digital Mission (ABDM) and the proliferation of e-pharmacies are enhancing access to medicines and streamlining patient care, further integrating the pharmaceutical sector with broader healthcare reforms.
Global regulatory
compliance and market access
India’s strong track record in regulatory compliance, including numerous USFDA and WHO-GMP approvals, has cemented its reputation as a reliable supplier of quality medicines to over 150 countries. This global recognition facilitates easier market entry and sustained demand for Indian pharmaceuticals.
Emerging trends reshaping the sector
Biosimilars and biologics With the expiration of patents on major biologic drugs, Indian firms are capitalizing on the opportunity to develop cost-effective biosimilars. The global biosimilars market is projected to reach $35–40 billion by 2030, and Indian companies are well-positioned to capture a significant share due to their expertise in large-scale, affordable manufacturing.
Custom manufacturing (CDMO) growth
India’s Contract Development and Manufacturing Organizations (CDMOs) are attracting global pharmaceutical companies seeking cost, skill, and scale advantages. The outsourcing of R&D and production to Indian CDMOs is expected to accelerate, especially post-pandemic, as companies seek resilient and diversified supply chains.
Sustainability and green chemistry
Increasing environmental regulations are prompting Indian pharmaceutical companies to adopt green manufacturing practices and sustainable waste disposal technologies. This shift not only ensures regulatory compliance but also enhances the sector’s global competitiveness.
Challenges: Hurdles on path to leadership
Despite its strengths, the Indian pharmaceutical industry faces several critical challenges:
- Overdependence on China for APIs: India imports approximately 65 per cent of its bulk drug needs from China, exposing the sector to supply chain vulnerabilities and geopolitical risks.
- Regulatory gaps: While large firms maintain high compliance standards, smaller players often struggle with uniform global regulatory requirements and quality assurance.
- Talent and skilling: The industry faces a shortage of professionals skilled in advanced areas such as data analytics, regulatory affairs, and biologics, necessitating focused talent development initiatives.
- R&D Investment: Indian pharmaceutical companies typically allocate only 7–8 per cent of revenue to R&D, significantly lower than global majors, potentially limiting innovation capacity.
Opportunities: The road ahead
API self-sufficiency
The government’s focus on API self-reliance through the PLI scheme and the development of bulk drug parks is expected to reduce import dependency and enhance export potential, particularly for high-value APIs like penicillin and cephalosporins.
Personalized medicine and AI integration
Indian firms are increasingly investing in AI-powered platforms for drug repurposing, clinical trials, and genomics-based drug development. The convergence of data science and pharmaceuticals opens up vast possibilities for personalized medicine and targeted therapies.
Global Contract Manufacturing (CDMO)
India’s reputation as a trusted manufacturing hub positions it favorably for global CDMO contracts. The post-pandemic emphasis on supply chain resilience is likely to drive more international companies to partner with Indian manufacturers.
Expansion into regulated markets
A strategic focus on complex generics, injectables, and inhalers is enabling Indian companies to penetrate highly regulated markets such as the US, EU, and Japan, where demand for specialized medicines continues to grow.
Therapeutic segments and market dynamics
The Indian pharmaceutical market’s growth is powered by both price-led expansion and new product introductions. In April 2025, the sector’s sales were primarily driven by price increases in high-demand categories such as cardiac, respiratory, and gastrointestinal therapies. Chronic disease management, particularly for conditions like hypertension, heart failure, and lipid disorders, remains a significant growth area.
New product launches in specialized care segments, such as stomatologicals and antineoplastics, are also contributing to market expansion, reflecting the industry’s focus on evolving therapeutic needs and specialty medicines.
Vision 2030: The Government’s ambitious roadmap
The Indian government has set an ambitious target to grow the pharmaceutical industry to $120–130 billion by 2030, up from approximately $50 billion in 2024. Key pillars of this vision include:
- Innovation-led growth through increased R&D investment and technology adoption
- API independence via domestic manufacturing and reduced import reliance
- Digital transformation of healthcare delivery and supply chains
- Global partnerships to enhance market access and technology transfer
- Strengthening regulatory frameworks to ensure quality and compliance
Industry platforms such as IPHEX, CPhI, and BioAsia are fostering strategic dialogue and collaboration between Indian firms and global stakeholders, further accelerating the sector’s growth trajectory.
Conclusion: India’s moment to lead
India’s pharmaceutical industry is undergoing a profound transformation, evolving from its traditional role as the world’s supplier of affordable generics to a research-driven, technology-integrated global healthcare powerhouse. This transition is not merely incremental- it represents a paradigm shift in how India is perceived and how it operates within the global pharmaceutical landscape.
Innovation and research
Indian pharmaceutical companies are increasingly investing in innovation, biosimilars, complex generics, and cutting-edge research. The integration of artificial intelligence, data analytics, and genomics is opening new frontiers in drug discovery, personalized medicine, and precision healthcare. These advancements are positioning India as a leader not just in manufacturing but also in the development of next-generation therapies and solutions.
Scale, efficiency and talent
India’s unparalleled manufacturing scale, cost efficiency, and deep reservoir of scientific talent provide it with a competitive edge. The country’s workforce, comprising skilled scientists, pharmacists, and engineers, is driving innovation and ensuring the highest standards of quality and compliance. This blend of scale and expertise enables India to meet both domestic healthcare needs and the growing demands of international markets.
Policy and sustainability
Continued government support through schemes like the PLI, coupled with a focus on sustainability and green chemistry, is fostering an environment conducive to long-term growth. The sector’s commitment to environmental responsibility and sustainable manufacturing practices is enhancing its global reputation and appeal.
Global partnerships and market access
India’s strategic collaborations with global pharmaceutical giants, research institutions, and regulatory bodies are expanding its footprint in regulated markets such as the US, EU, and Japan. These partnerships are facilitating technology transfer, knowledge exchange, and access to new markets, further accelerating the industry’s growth trajectory.
Societal impact and vision
At its core, the Indian pharmaceutical industry remains committed to its foundational mission: delivering accessible, affordable, and advanced medicines to people across the world. The sector’s growth has improved healthcare outcomes, reduced disease burdens, and enhanced the quality of life for millions, both in India and globally.
With continued policy support, increased investment in R&D, and a relentless focus on digital and sustainable transformation, India is poised to redefine its role in the global pharmaceutical ecosystem. The vision for the future is clear- a sector that not only meets the world’s demand for affordable medicines but also leads in innovation, research, and healthcare delivery.
India’s moment to lead has arrived. The country’s pharmaceutical industry stands ready to shape the future of global healthcare, setting new benchmarks in accessibility, affordability, and advancement. As India steps confidently into this new era, it carries with it the promise of better health and well-being for all.
(The author is Scientific Advisor of ALKOMEX GBN PHARMA USA)
|